Adial Pharmaceuticals Stock Soars 55.69% on Drug Progress

Adial Pharmaceuticals' stock surged 55.69% in pre-market trading on June 26, 2025, marking a significant milestone for the company.

Adial Pharmaceuticals has made substantial progress with its flagship drug, AD04, which is designed to treat Alcohol Use Disorder (AUD). The company has recently signed agreements with Cambrex and Thermo Fisher Scientific to support the production of AD04 and prepare for its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA).

These agreements are crucial for advancing the clinical trials of AD04 and ensuring the necessary manufacturing stages are covered. The collaboration with Thermo Fisher Scientific and Cambrex has already led to the completion of essential demonstration batches, a key step before proceeding to registration and clinical batches.

AD04 is a genetically targeted therapy that focuses on serotonin-3 receptor antagonism, aiming to aid heavy drinking patients. The company's efforts to bring a new treatment option for AUD to the market are gaining momentum with these strategic partnerships.